Please assess the completion status of the following clinical trial:

Trial Title: Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who is \>=18 years.~* Term pregnancy \> 37 weeks~* Induction of labor in progress, medically indicated~* Patients who have had the establishment of a first Propess®, within 24 to 36 hours (before signing the consent)~* Cephalic presentation~* Unfavorable cervical conditions (Bishop score \<6) 1 hour prior to inclusion~* Intact Membranes~* Affiliated with a social security system~* Having signed the consent form.~Exclusion Criteria:~* Multiple pregnancy~* Uterus scar~* Contraindications to epidural anesthesia~* Contraindications to Propess®: recent history of pelvic inflammatory disease; hypersensitivity to prostaglandins Adverse effects appeared in the first Propess®: anaphylactic shock, disseminated intravascular coagulation (DIC).~* Contraindications to Syntocinon: Hypersensitivity to oxytocin, cardiovascular disorders and severe toxemia of pregnancy.~* Contraindications to vaginal delivery (placenta previa, previa obstacle ...)~* Premature Rupture of Membranes (PROM)~* Intra Uterine Growth Retardation (IUGR) \<3rd percentile~* Macrosomia\> 97th percentile~* Severe Impaired fetal heart rate~* In Utero Fetal Death (IUFD)~* Medical Termination of pregnancy or lethal fetal pathology~* Patient under guardianship or trusteeship safeguard justice

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dinoprostone (Type: EXPERIMENTAL): In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
- Oxytocine (Type: ACTIVE_COMPARATOR): In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).